Switzerland· 69150001
Orgovyx 120 mg, Filmtabletten
A relugolix product containing relugolixum, registered in Switzerland by Accord Healthcare AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Relugolix is registered in 15 of 19 countries.
Countries holding a registration under ATC L02BX04 (relugolix), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 10 of them publish a price we can compare per daily dose
Relugolix · ATC L02BX04
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of relugolix costs, country by country.
Normalised to the WHO defined daily dose (0.12 g), the median price runs from $3.40 in France to $9.83 in Italy — a ×2.9 gap.
- Switzerland: $6.03 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Relugolix · price per daily dose (0.12 g)
USD · FX 28 Sept 2026
- IT Italy$9.83
- ES Spain$7.69
- CH Switzerland$6.03
- FR France$3.40
The record
At a glance
Swissmedic (Switzerland)- Active substance
- relugolixum
- Manufacturer
- Accord Healthcare AG
- Country
- Switzerland (CH)
- ATC code
- L02BX04
- ATC class
- Relugolix
- Defined daily dose
- 0.12 g, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680691500015Fl 30 StkCHF 149.95
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
168 interactions on record for relugolix.
Graded by severity as the source publishes them — 52 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Relugolix · interactions on record
168 records
- 52 severe
- 101 moderate
- 15 minor
Most severe, free to view
- PapaverineA03AD01severe
- DolasetronA04AA04severe
- RolapitantA04AD14severe
- FidaxomicinA07AA12severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Relugolix in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaORGOVYXAccord Healthcare S.L.U., Barcelona
- FinlandOrgovyxAbacus Medicine A/S
- NorwayOrgovyxAccord Healthcare S.L.U.
- IrelandOrgovyx 120 mg film-coated tabletsAccord Healthcare S.L.U.
- IcelandOrgovyxAccord Healthcare S.L.U.
- NetherlandsOrgovyx 120 mg, filmomhulde tablettenAccord Healthcare S.L.U.
- PolandOrgovyxAccord Healthcare S.L.U.
- SwedenOrgovyx 120 mg Filmdragerad tablettAccord Healthcare S.L.U.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Orgovyx
- Liechtenstein · Orgovyx
- Norway · Orgovyx
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/105046fb-5cfe-4d1f-8459-da7a94ec57c5 GET /v1/drugs/105046fb-5cfe-4d1f-8459-da7a94ec57c5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "relugolixum 120 mg",
"valid_from": "2024-01-01",
"limitations": null,
"galenic_form": "Filmtabl 120 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2024-01-01",
"self_retention_pct": 10
}See everything about relugolix.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.